Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 40INDUSTRY 17NETWORK 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9Gastrointestinal 8Genitourinary 4Breast 3Tumor-Agnostic 2Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Cisplatin 38Radiotherapy 35Magnetic Resonance Spectroscopy 32Specimen Handling 22Cetuximab 18Fluorouracil 17Radiotherapy, Intensity-Modulated 16Platinum 161,2-diaminocyclohexaneplatinum II citrate 16Biopsy 15Paclitaxel 13Carboplatin 13Nivolumab 11Docetaxel 10pembrolizumab 8Radiation 8Fluorodeoxyglucose F18 8Erlotinib Hydrochloride 8Bortezomib 8Bevacizumab 8Gemcitabine 7Sorafenib 6Immunoglobulin G 6Disulfides 6aldesleukin 5Hydroxyurea 5Gefitinib 5Chemotherapy, Adjuvant 5(225)Ac-DOTA-c(RGDyK) 5cabozantinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × durvalumab × Head & Neck × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡